Patients were evaluated clinically, with liver & renal function tests every month and HBeAg/ anti HBe and HBV DNA levels every 3–6 months for biochemical (normalization of ALT), serological see more (HBeAg loss/ seroconversion) and virological (HBV DNA < 2.06 log copies/ml) response as well as for renal toxicity. Results: Results: The patients included 52 males, 28 females of median age 43
years range 18–78 years. Forty-eight patients (60%) had cirrhosis. The median baseline ALT levels were 150 IU/l (range 60–412) and median HBV DNA levels were 7.1 log copies/ml (range 4.6–7.4). After one, two and three years of treatment the biochemical response was seen in 70%, 85% and 95%, serological response in 26.3%, 37.5% and 62.5% and virological response in 56.3%, 78.8% and 91.3% respectively. Five patients had breakthrough hepatitis and mild renal impairment was noted in 3 cirrhotic patients. Conclusion: Conclusion: Combination therapy of lamivudine and adefovir proved to be safe and effective in
achieving biochemical, serological and virological learn more response in our HBeAg positive predominantly cirrhotic patients of chronic hepatitis B. Key Word(s): 1. chronic hepatitis B; 2. HBeAg positive; 3. combination therapy; 4. lamivudine, adefovir; Presenting Author: JUAN LV Additional Authors: YU PAN, JING JIANG, RUIHONG
WU, HAIBO SUN, XIUMEI CHI, XIAOMEI WANG, JUNQI NIU Corresponding Author: JUNQI NIU Affiliations: The first hospital of Jilin university; The first hospital of Jilin university Objective: Interferon-gamma inducible protein 10 kDa is a chemotactic CXC chemokine discovered in 1985, IP-10 plays an important role in the immune responseand development of chronic viral hepatitis. Many studies have shown that, the high level expression of IP-10 was detected in liver and serum of patients with chronic hepatitis C. The high level expression of IP-10 Aprepitant is closely related with the degree of hepatic inflammatory and fibrosis. At present, the relationship between IP-10 and therapeutic efficacy after antiviral treatment is not clear Methods: In this study, we use enzyme-linked immunosorbent assay to clarify the difference in levels of plasma IP-10 in patients with chronic hepatitis C, spontaneous clearance and healthy controls; The level of IP-10 was observed in the plasma of patients with chronic hepatitis C before treatment, during treatment and after treatment; Find the best threshold of IP-10 level which can predict the therapeutic efficacy of antiviral therapy Results: The plasma IP-10 level of spontaneous clearance group were low than in the chronic hepatitis C group and healthy control group.